

【Therapeutic category】 Antibiotic preparations acting mainly on mold

【Non-proprietary name】 Posaconazole

【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozone, quinidine sulfate hydrate, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, lemborexant hydrate, daridorexant hydrochloride, finerenone, eplerenone, azelnidipine, olmesartan medoxomil/azelnidipine, mavacamten, lonafarnib, palovarotene, lurasidone hydrochloride, blonanserin, voclosporin, triazolam, rivaroxaban 10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the	2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, methylergometrine, ergometrine, simvastatin, atorvastatin, pimozone, quinidine sulfate hydrate, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], suvorexant, lemborexant hydrate, daridorexant hydrochloride, finerenone, eplerenone, azelnidipine, olmesartan medoxomil/azelnidipine, mavacamten, lonafarnib, palovarotene, <u>anamorelin hydrochloride</u>, lurasidone hydrochloride, blonanserin, voclosporin, triazolam, rivaroxaban 10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the

following.) (N/A)	following.)		
	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
	<u>Anamorelin hydrochloride</u>	<u>The effect of anamorelin hydrochloride may be enhanced.</u>	<u>The plasma concentration of anamorelin hydrochloride is expected to increase due to the inhibition of CYP3A4 by co-administration with posaconazole.</u>

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.